GLP-1 Dosing Schedules Explained
Why GLP-1 doses start low and step up slowly, what the typical semaglutide and tirzepatide schedules look like, and how to handle a rough week.
6 min read · Last reviewed 2026-09-01 by the TopGLP1 Editorial Team
Educational, not medical advice. This page explains GLP-1 medications in general terms. Only a licensed clinician who knows your history can decide what's right for you.
Key takeaways
- Every GLP-1 starts low and increases every 4 weeks to limit nausea.
- The starter dose isn't meant to cause much weight loss — it's for tolerance.
- You don't always need the maximum dose to get results.
- Slowing down escalation is a normal, safe response to side effects.
Why the slow ramp-up
Every GLP-1 medication is dose-escalated: you start at a low dose and increase it in steps, usually every four weeks. This isn't bureaucracy — it's the single most important thing that determines whether your first two months are tolerable.
Starting at a full dose overwhelms the gut and causes severe nausea and vomiting. The gradual schedule lets your digestive system adapt to slower emptying before the appetite effect is turned up.
The typical semaglutide (Wegovy) schedule
- Weeks 1–4: 0.25 mg weekly (starter — tolerance, not weight loss)
- Weeks 5–8: 0.5 mg weekly
- Weeks 9–12: 1.0 mg weekly
- Weeks 13–16: 1.7 mg weekly
- Week 17 onward: 2.4 mg weekly (maintenance)
The typical tirzepatide (Zepbound) schedule
- Weeks 1–4: 2.5 mg weekly (starter)
- Weeks 5–8: 5 mg weekly (first therapeutic dose)
- Weeks 9–12: 7.5 mg weekly
- Weeks 13–16: 10 mg weekly
- Then, if needed: 12.5 mg → 15 mg weekly
You may not need the top dose
The maximum dose is a ceiling, not a target. Plenty of people reach their goal weight and feel great at an intermediate dose — 1.0 mg semaglutide or 5–10 mg tirzepatide — and never go higher. The right dose is the lowest one that keeps you progressing with manageable side effects.
When a week is rough
If a dose increase brings side effects you can't live with, the standard move is to hold at your current dose for another few weeks rather than push up, or to step back down. This is normal and safe, and a good clinician expects it. What you should not do is double up after a missed dose or accelerate the schedule to “catch up.”
Compounded products can differ in concentration between pharmacies, so dose by the milligrams your prescriber specifies, not by lines on the syringe.
Sources & references
Clinical figures on this page trace to peer-reviewed trials and official regulators. We link the primary record so you can verify it yourself.
- 1.Wilding JPH, et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity. N Engl J Med. 2021;384(11):989–1002.Clinical trialNew England Journal of Medicine
- 2.Jastreboff AM, et al. Tirzepatide Once Weekly for the Treatment of Obesity. N Engl J Med. 2022;387(3):205–216.Clinical trialNew England Journal of Medicine